Surge in incidence of chronic wounds such as
diabetic foot ulcers, pressure ulcers, radiation wounds, infectious wounds,
arterial ulcers, and acute wound including burn and trauma drives the demand
for wound debridement. Improving the quality of lives of patients suffering
chronic wounds is a major aim for researchers and companies operating in the
wound debridement sector and wound care space. Research institutes and
researchers from universities across the world are conducting trials and
revealing results. They researched the effectiveness of wound debridement for
complex foot infections along with venous leg ulcers (VLUs). Researchers from
different organizations and institutes from the U.S. and the U.K. are on the
forefront of developing new wound debridement options for patients suffering
from chronic wounds. They aim to develop innovative solutions and launch products
that would become preferred options for patients and enhance the quality of
lives. Clinical trials have been conducted and conclusions for various phases
of trials have been drawn. The further steps will help these companies and
organizations in gaining approval for their products. Innovative products and
options will become available in the coming years. According to the report
published by Allied Market Research, the global wound
debridement market is estimated to reach $5.67 billion by 2030.
Following are some of the activities taking place across the world.
Researchers from the U.K. conducted a research
in which they treated complex foot infections with surgical debridement along
with antibiotics containing calcium sulfate. These infections contain soft and
bone tissues in patients suffering from peripheral arterial disease (PAD) and
diabetes. The courses of systematic antibiotics led to high economic costs,
side effects of drugs, and antimicrobial resistance.
In the new research, researchers determined the
effectiveness of surgical debridement along with antibiotics containing calcium
sulfate on resolving foot infections and healing of wounds. In a research
conducted on 137 patients, they measured outcomes regarding resolution of infection,
time required for healing, and duration for which postoperative antibiotics were
used. The outcomes showed that nearly 88% of infections were resolved. For 22
patients, postoperative systemic antibiotics were not needed. The average
healing time required was nearly 11.3 weeks. The healing time surged
considerably for patients suffering from PAD and diabetes. In conclusion,
researchers stated that surgical debridement and antibiotics containing calcium
sulfate are effective and safe for management of complex foot infections.
Biopharmaceutical companies are also conducting
trials for testing effectiveness of debridement for various conditions. MediWound
Ltd., a biopharmaceutical company focused on development of biotherapeutic solutions
for tissue repair and regeneration, concluded the phase two of the clinical
study of EscharEx for venous leg ulcers (VLUs) debridement. The company
highlighted that the study reached the primary endpoint. It showed the high
degree of statistical significance and concluded that patients treated with EscharEx
had a considerably high incidence of entire debridement. Moreover, the
effectiveness of EscharEx was statistically higher even when compared to gel
vehicle. Researchers also observed the favorable reduction in wound area and
pain as compared to application of gel vehicle.
Commenting on the end of phase two, Sharon
Malka, the Chief Executive Officer of MediWound, stated that this result shows
that the potential benefits of EscharEx on patient lives in terms of clinical
and physical outcomes. EscharEx is only a step away from becoming the
best-in-class and non-surgical debridement choice for patients undergoing
chronic wounds. The company would enter the billion-dollar market of chronic
wound care and gain a major market share with implementation of EscharEx. It
will advance toward the phase three of the EscharEx clinical program. Such
research activities and clinical trials will bring a new option for wound
debridement and transform the wound healing process.
Author Bio
Email: pratik.kirve@alliedmarketresearch.net
LinkedIn: https://www.linkedin.com/in/pratik-kirve-8213b284/
Pratik Kirve is a writer, blogger, and sport enthusiast. He holds a bachelor’s degree in Electronics and Telecommunication Engineering, and is currently working as a Team Lead - Content Writing at Allied Market Research. He has an avid interest in writing news articles across different verticals. When he is not following updates and trends, he spends his time reading, writing poetry, and playing football.
Comments
Post a Comment